SurModics Stock News

Here are four top-performing liquid stocks, Deckers Outdoor (DECK), Surmodics (SRDX), NVIDIA (NVDA) and Sprinklr (CXM), which investors can add to their portfolio for solid returns.

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Here are four top-ranked liquid stocks, Surmodics (SRDX), Fluor Corporation (FLR), NVIDIA (NVDA) and Sprinklr (CXM), which investors can add to their portfolio for solid gains.

Investors are optimistic about Surmodics' (SRDX) consistent efforts to boost R&D.

Here are four top-ranked liquid stocks, Surmodics (SRDX), Fluor Corporation (FLR), NVIDIA (NVDA) and GigaCloud Technology (GCT), which investors can add to their portfolio for solid gains.

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and NVIDIA (NVDA), which investors can add to their portfolio for solid gains.

Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and GigaCloud Technology (GCT), which investors can add to their portfolio for solid gains.

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Needham--SRDX, a provider of medical device and in vitro diagnostic technologies, announced management will participate in upcoming investor conferences.

Surmodics, Inc. (NASDAQ:SRDX ) Q3 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Gary Maharaj - President & Chief Executive Officer Timothy Arens - Chief Financial Office

Surmodics (SRDX) reports a solid fiscal third quarter top line on the back of robust Medical Device revenues.

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimat

SurModics (SRDX) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $0.46 per share. This compares to loss of $0.34 per share a year ago.

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Surmodics is a medical device maker that makes coatings for medical devices and manufactures chemicals for diagnostic immunoassay tests The company will make a drug-coated balloon that will be sold by